Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus DICYCLOMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus DICYCLOMINE HYDROCHLORIDE.
CANTIL vs DICYCLOMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
10-20 mg orally 3-4 times daily
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic